Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 599

1.

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.

Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.

Clin Neurol Neurosurg. 2006 Feb;108(2):124-8.

PMID:
16412833
3.

Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.

Yushchenko M, Mäder M, Elitok E, Bitsch A, Dressel A, Tumani H, Bogumil T, Kitze B, Poser S, Weber F.

J Neurol. 2003 Oct;250(10):1224-8.

PMID:
14586607
4.

Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.

Comabella M, Río J, Espejo C, Ruiz de Villa M, Al-Zayat H, Nos C, Deisenhammer F, Baranzini SE, Nonell L, López C, Julià E, Oksenberg JR, Montalban X.

Clin Immunol. 2009 Feb;130(2):145-50. doi: 10.1016/j.clim.2008.09.010. Epub 2008 Oct 21.

PMID:
18945642
6.

IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.

Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D.

Neurology. 2003 Jan 14;60(1):52-7.

PMID:
12525717
7.

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.

Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K.

Neurology. 1999 Oct 22;53(7):1397-401.

PMID:
10534241
8.

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D.

Brain. 2004 Feb;127(Pt 2):259-68. Epub 2003 Nov 7.

PMID:
14607790
9.

Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.

Bernal F, Elias B, Hartung HP, Kieseier BC.

Mult Scler. 2009 Jun;15(6):721-7. doi: 10.1177/1352458509102920. Epub 2009 Apr 21.

PMID:
19383643
10.

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.

Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.

Arch Neurol. 2008 Feb;65(2):199-204. Epub 2007 Dec 10.

PMID:
18071030
11.

The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.

Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP.

Arthritis Rheum. 2000 Feb;43(2):270-4.

12.

Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.

Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, Kadanka Z, Bednarík J.

Mult Scler. 2009 Mar;15(3):316-22. doi: 10.1177/1352458508099482. Epub 2009 Jan 19.

PMID:
19153173
13.

Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.

Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.

J Neurol. 2003 Sep;250(9):1037-43.

PMID:
14504963
14.

Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes.

Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M.

J Neuroimmunol. 2003 Mar;136(1-2):46-53.

PMID:
12620642
15.

Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.

Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P.

Neurology. 1999 Oct 22;53(7):1402-8.

PMID:
10534242
16.

Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.

Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfrinato MC, Baldi E, Tola MR, Dallocchio F, Granieri E, Bellini T.

Mult Scler. 2009 May;15(5):547-54. doi: 10.1177/1352458509102372. Epub 2009 Mar 24.

PMID:
19318509
17.

Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.

Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawa M, Yoshihara H, Naito M, Miyamoto T, Inoue A, Asai A, Hijioka T, Fusamoto H, Kamada T.

J Hepatol. 1997 Mar;26(3):574-83.

PMID:
9075665
18.

Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.

Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X.

J Neurol. 2005 Jul;252(7):795-800. Epub 2005 Mar 18.

PMID:
15772741
19.

Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis.

Lichtinghagen R, Seifert T, Kracke A, Marckmann S, Wurster U, Heidenreich F.

J Neuroimmunol. 1999 Sep 1;99(1):19-26.

PMID:
10496173
20.

Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.

Sellner J, Greeve I, Leib SL, Mattle HP.

Arch Neurol. 2008 May;65(5):672-4. doi: 10.1001/archneur.65.5.672. No abstract available.

PMID:
18474748

Supplemental Content

Support Center